Figure 1
Neoadjuvant chemotherapy (NAC) and biobanking schedule of the Q-CROC-03 study. An illustration of the schedule of various chemotherapy regimens with the biobanking collection schedule superimposed. Tissue sample collection occurred before the start of NAC at the time of diagnosis (B1), and then either after NAC (B2) and/or at surgery (S3) in the case of non-pCR patients. Up to 5 blood samples were collected: 1 before the start of NAC at baseline (T0), 1 after the 1st cycle of the 1st drug regimen (T1), 1 at mid-treatment or at the switch between the 2 drugs regimen (T2), 1 after the 1st cycle of the 2nd drug regimen (T3), 1 at the end of NAC (T4) before surgery). The different NAC drug regimens were AC + Tax [4 cycles of Doxorubicin (or Epirubicin) with Cyclophosphamide followed by 12 cycles of weekly Paclitaxel, or 3 cycles of 5-Fluorouracil/Epirubicin/Cyclophosphamide followed by 12 cycles of weekly Paclitaxel (or 3 cycles of Docetaxel)]; Tax + AC (12 cycles of weekly Paclitaxel followed by 4 cycles of Doxorubicin (or Epirubicin) with Cyclophosphamide, or 3 cycles of 5-Fluorouracil/Epirubicin/Cyclophosphamide); Tax only (12 cycles of weekly Paclitaxel); or ACTax (3 or 4 cycles of Doxorubicin with Cyclophosphamide + Docetaxel, or 4 cycles of Carboplatin/Paclitaxel).
